What is the 13F Pro Quality Score for INVA?

13F Pro ranks Innoviva, Inc. (INVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INVA's current score at https://13fpro.ai/research/INVA (free sign-up required for the full ranking).

Where does 13F Pro source INVA data?

All Innoviva, Inc. fundamentals and ownership data come directly from SEC EDGAR. Innoviva, Inc. files with the SEC under CIK 1080014. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INVA in?

Innoviva, Inc. (INVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INVA research updated on 13F Pro?

INVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Innoviva, Inc.(INVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1080014 INVA stock profile & AI dashboard →

13F Pro Quality Score

75.2/100

Rank #136 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

73.6/100

Profitability

96.1/100

Balance Sheet

95.5/100

Earnings Quality

80.3/100

Free Cash Flow

91.5/100

Institutional Flow

45.5/100

Revenue Scale

33.2/100

Dilution Risk

38.9/100

INVA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Innoviva, Inc. (INVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INVA at 75.2/100 on a 32-signal composite quality model, placing it at rank #136 of 2,879 stocks — the top 5% of the AI-ranked universe. INVA scores in the top quartile across profitability (96.1), balance sheet strength (95.5), free cash flow (91.5). Areas of concern include revenue scale (33.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Innoviva, Inc. reports quarterly revenue of $98.0M, net income of $186.6M, an operating margin of 38.9%. Top institutional holders of INVA by reported 13-F value include BlackRock,, DIMENSIONAL FUND ADVISORS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. INVA trades on the Nasdaq exchange and files with the SEC under CIK 1080014. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Innoviva, Inc. directly from SEC EDGAR.

✦

Fun facts about Innoviva, Inc.

Quirks, history, and lore behind INVA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in California · focused on royalties and royalty-like assets in pharmaceuticals.
2
The Numbers
A small-cap company whose revenue is heavily tied to royalty streams from a handful of respiratory drug products — lean headcount, but the checks keep coming.
3
The History
Spun out of GlaxoSmithKline's former partner company, it was restructured in the 2010s to pivot away from drug development and toward collecting passive royalties.
4
The Secret
It doesn't make drugs, market drugs, or employ armies of scientists — it simply owns the royalty rights to drugs that other companies sell, like a landlord who never fixes anything.
5
The Lore
Its biggest royalty cash cow is tied to RELVAR/BREO ELLIPTA and ANORO ELLIPTA — blockbuster respiratory inhalers developed and sold by GSK.
6
The Giveaway
Ticker spells out a hint: this innovator-turned-royalty-collector sits back while GlaxoSmithKline's inhaler sales pay its bills — forever known by its four-letter symbol, INVA.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$98.0M

Net Income

Q1 2026

$186.6M

Free Cash Flow

Q1 2026

$34.8M

Operating Margin

Q1 2026

38.9%

D/E Ratio

Q1 2026

0.19

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+14.7% YoY

$411.3MFY 2025

FY21 $391.9MFY23 $310.5MFY24 $358.7MFY25 $411.3M

Operating Income

-1.9% YoY

$163.7MFY 2025

FY21 $375.1MFY23 $113.9MFY24 $166.9MFY25 $163.7M

EPS (Diluted)

+816.7% YoY

$3.30FY 2025

FY21 $2.87FY23 $2.20FY24 $0.36FY25 $3.30

Total Assets

+25.7% YoY

$1.64BFY 2025

FY21 $926.4MFY23 $1.24BFY24 $1.30BFY25 $1.64B

Total Debt

-42.5% YoY

$257.7MFY 2025

FY21 $394.7MFY23 $446.2MFY24 $448.3MFY25 $257.7M

Op. Cash Flow

+4.4% YoY

$196.9MFY 2025

FY21 $363.8MFY23 $141.1MFY24 $188.7MFY25 $196.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$411.3M +14.7%	$358.7M +15.5%	$310.5M -20.8%	$391.9M +16.4%	$336.8M +29.0%	$261.0M
Operating Income	$163.7M -1.9%	$166.9M +46.5%	$113.9M -69.6%	$375.1M +16.8%	$321.1M +30.3%	$246.4M
EPS (Diluted)	$3.30 +816.7%	$0.36 -83.6%	$2.20 -23.3%	$2.87 +42.1%	$2.02 +41.3%	$1.43
Total Assets	$1.64B +25.7%	$1.30B +4.6%	$1.24B +34.2%	$926.4M -7.3%	$999.6M +37.9%	$724.8M
Total Debt	$257.7M -42.5%	$448.3M +0.5%	$446.2M +13.1%	$394.7M +2.4%	$385.5M +2.2%	$377.1M
Operating Cash Flow	$196.9M +4.4%	$188.7M +33.8%	$141.1M -61.2%	$363.8M +16.2%	$313.1M +21.6%	$257.5M

Get alerted when INVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Innoviva, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INVA

BlackRock, Inc.
$263.5M11,307,845 sh
DIMENSIONAL FUND ADVISORS LP
$103.4M4,436,427 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$98.4M4,224,951 sh
RENAISSANCE TECHNOLOGIES LLC
$94.5M4,055,632 sh
VANGUARD CAPITAL MANAGEMENT LLC
$73.2M3,141,581 sh
STATE STREET CORP
$71.3M3,060,377 sh
MILLENNIUM MANAGEMENT LLC
$53.1M2,279,451 sh
Sarissa Capital Management LP
$49.7M2,130,950 sh
SYSTEMATIC FINANCIAL MANAGEMENT LP
$47.2M2,024,082 sh
LINDEN ADVISORS LP
$46.0M42,396,000 sh

Fund	Value	Shares
BlackRock, Inc.	$263.5M	11,307,845
DIMENSIONAL FUND ADVISORS LP	$103.4M	4,436,427
VANGUARD PORTFOLIO MANAGEMENT LLC	$98.4M	4,224,951
RENAISSANCE TECHNOLOGIES LLC	$94.5M	4,055,632
VANGUARD CAPITAL MANAGEMENT LLC	$73.2M	3,141,581
STATE STREET CORP	$71.3M	3,060,377
MILLENNIUM MANAGEMENT LLC	$53.1M	2,279,451
Sarissa Capital Management LP	$49.7M	2,130,950
SYSTEMATIC FINANCIAL MANAGEMENT LP	$47.2M	2,024,082
LINDEN ADVISORS LP	$46.0M	42,396,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INVA on your watchlist

Track score changes the day Innoviva, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INVA a good stock to buy?

13F Pro's AI-powered analysis of Innoviva, Inc. (INVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INVA are available on the INVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Innoviva, Inc.'s investment landscape.